Current problems in cancer. Case reports最新文献_第10页

A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan 一例罕见的晚期化生性乳腺癌对舒妥珠单抗治疗有反应

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100239

Sharlene Dong , Yisheng Fang , Samira Syed

引用次数: 0

Chronic lymphocytic leukemia in the female pelvis: A case series illustrating the diagnostic challenges 女性骨盆慢性淋巴细胞白血病：一系列病例说明诊断挑战

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100234

Alexandra Morell , Sarah Thappa , Naixin Zhang , Rachael Rowswell-Turner , Lila Marshall , Cynthia Angel , Brent DuBeshter , Bradley Turner , Richard Moore , Ashlee Smith

引用次数: 0

NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature NCOA-RET融合作为奥西美替尼在复杂EGFR突变肺腺癌中的二次耐药机制：病例报告和文献复习

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100232

Alberto P. Romagnolo , Christopher Hino , Saied Mirshahidi , Kristina Chase , Hamid Mirshahidi

引用次数: 0

Clinically significant radiation necrosis following trastuzumab-deruxtecan and brain stereotactic radiosurgery: A case series in breast cancer patients trastuzumab-deruxtecan和脑立体定向放射外科术后临床显著的放射坏死：癌症患者的病例系列

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100242

Victoria Wytiaz , Anne Schott , Aki Morikawa , Michelle M. Kim

{"title":"Clinically significant radiation necrosis following trastuzumab-deruxtecan and brain stereotactic radiosurgery: A case series in breast cancer patients","authors":"Victoria Wytiaz , Anne Schott , Aki Morikawa , Michelle M. Kim","doi":"10.1016/j.cpccr.2023.100242","DOIUrl":"10.1016/j.cpccr.2023.100242","url":null,"abstract":"<div><p>An estimated 15% of breast cancers in the United States overexpress human epidermal growth factor receptor 2 (HER2), and patients with HER2+ breast cancer have an increased risk of developing brain metastases. The recent development of HER2-targeted agents, including trastuzumab deruxtecan (T-DXd), has resulted in improved systemic disease control, including disease metastasized to the brain. Because many patients with brain metastases have received both T-DXd and have also undergone brain stereotactic radiosurgery (SRS), it is important to explore the interaction of these treatment modalities. Here, we present two cases of clinically significant radiation necrosis (CSRN) occurring in patients with metastatic breast cancer with a treatment history including brain SRS and T-DXd. We also briefly describe two additional cases of CSRN in patients with the additional remote treatment history of trastuzumab emtansine (T-DM1) prior to T-DXd, as T-DM1 has also been reported to cause increased rates of CSRN in patients with HER2+ metastatic breast cancer with a history of SRS-treated brain metastases. While case reports and series have illustrated this phenomenon with T-DM1, no existing literature has described these findings with T-DXd. We describe these cases and review the potential etiologies for CSRN in this specific patient population, thus highlighting the need for a more thorough understanding of the potential adverse events caused by the intersection of treatment modalities, namely brain SRS and HER2-directed antibody-drug conjugates as the landscape of targeted therapies continues to evolve.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44421604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sinonasal teratocarcinosarcoma treated via endonasal endoscopic approach and CyberKnife radiotherapy: A case report and review of the literature 经鼻内窥镜入路加CyberKnife放射治疗鼻腔畸胎瘤肉瘤1例报告并文献复习

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100233

Shiori Tanaka , Hidenori Yokoi , Kohei Inomata , Keisuke Maruyama , Masachika Fujiwara , Arisa Ohara , Shoji Naito , Koichiro Saito

{"title":"Sinonasal teratocarcinosarcoma treated via endonasal endoscopic approach and CyberKnife radiotherapy: A case report and review of the literature","authors":"Shiori Tanaka , Hidenori Yokoi , Kohei Inomata , Keisuke Maruyama , Masachika Fujiwara , Arisa Ohara , Shoji Naito , Koichiro Saito","doi":"10.1016/j.cpccr.2023.100233","DOIUrl":"10.1016/j.cpccr.2023.100233","url":null,"abstract":"<div><p>Teratocarcinosarcoma is an extremely invasive high-grade malignancy that develops in the nasal cavity and paranasal sinus, with pathological features of both teratoma and carcinosarcoma. Here, we present a case of primary teratocarcinosarcoma in the sphenoid sinus along with a review of the literature. A 70-year-old woman presented to our hospital with chief complaints of diplopia, photophobia in the right eye, and dull pain in the back of the right eyeball. Ophthalmological examination showed no abnormalities, and head magnetic resonance imaging showed a tumoral lesion extending from the sella turcica to the sphenoid sinus. Endonasal endoscopic removal of the malignant tumor was performed under general anesthesia. Intraoperative findings revealed that the posterior wall of the sphenoid sinus had thinned out because of compression by the tumor, which had adhered to the dura mater and internal carotid artery. This made total excision difficult, and the tumor was removed as much as possible. Based on pathological examination, the tumor was diagnosed as a teratocarcinosarcoma. Since postoperative magnetic resonance imaging suggested the presence of residual tumor, irradiation was administered at a dose of 36 Gy in 12 fractions with CyberKnife. Subjective symptoms, including diplopia, showed improvement, and imaging showed regression of the lesion. The patient has had an uneventful course without recurrence for 40 months. Maximal safe excision via endonasal endoscopic approach combined with the use of CyberKnife is a potentially useful and minimally invasive treatment method for teratocarcinosarcoma in the sphenoid sinus.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43728652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical management of secretory breast carcinoma in children 儿童分泌性乳腺癌的手术治疗

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100229

Sylvia Mazellier , Mousselim Gharbi , Marie Pate , Marie-Pierrette Chenard , Catherine Bruant-Rodier , Sarah Jannier , Shanti Ame , Massimo Lodi , Carole Mathelin

引用次数: 0

Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report 一例转移性MET外显子14跳过非小细胞肺癌癌症且表现不佳的高症状患者对替普替尼的显著反应：病例报告

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100230

Sebastian Kraus

{"title":"Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report","authors":"Sebastian Kraus","doi":"10.1016/j.cpccr.2023.100230","DOIUrl":"https://doi.org/10.1016/j.cpccr.2023.100230","url":null,"abstract":"<div><p>Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial evidence in patients with poor performance status is often sparse, especially for newer drug classes. Tepotinib, an oral, once-daily MET inhibitor, was recently approved for the treatment of advanced/metastatic NSCLC with <em>MET</em> exon 14 (<em>MET</em>ex14) skipping based on the durable clinical activity observed in the Phase II VISION trial. We report an excellent response to tepotinib in a patient with metastatic NSCLC with <em>MET</em>ex14 skipping, which was achieved despite a poor baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 3, substantial symptom burden, and prior intolerance to chemotherapy. The patient attained a rapid, near-complete radiographic response, evident from the first tumor assessment at 2 months, which was maintained for >8 months (ongoing at the time of writing) and correlated with the alleviation of all disease-related symptoms and improvement in ECOG PS to 0. Tepotinib was well tolerated despite the poor clinical condition and prior intolerance to chemotherapy. This case report provides real-world evidence for the clinical effectiveness of tepotinib and indicates that a dramatic response can be attained without clinically significant adverse events, even in a patient who would typically be ineligible for clinical trials due to poor ECOG PS.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49801657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Afatinib-induced bronchiolitis obliterans 阿法替尼诱导的闭塞性支气管炎

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100231

Tadayuki Nakashima, Yoshimasa Shiraishi, Ayaka Shiota, Yasuto Yoneshima, Eiji Iwama, Kentaro Tanaka, Isamu Okamoto

{"title":"Afatinib-induced bronchiolitis obliterans","authors":"Tadayuki Nakashima, Yoshimasa Shiraishi, Ayaka Shiota, Yasuto Yoneshima, Eiji Iwama, Kentaro Tanaka, Isamu Okamoto","doi":"10.1016/j.cpccr.2023.100231","DOIUrl":"10.1016/j.cpccr.2023.100231","url":null,"abstract":"<div><p>We report a case of bronchiolitis obliterans (BO) due to afatinib treatment. A 42-year-old woman was diagnosed with stage IVB lung adenocarcinoma (cT1bN3M1c) positive for the L861Q mutation of <em>EGFR</em> and was treated with afatinib. Seven months after the onset of afatinib therapy, she presented with a cough that gradually worsened despite treatment for bronchial asthma. Pulmonary function tests showed severe obstructive patterns that were not improved with inhaled bronchodilators. Chest computed tomography revealed a mosaic attenuation pattern, and pulmonary ventilation-perfusion scintigraphy showed a matched defect. She had no underlying causes of secondary BO, and she was therefore diagnosed with afatinib-induced BO. Respiratory function did not deteriorate further after discontinuation of afatinib or after subsequent treatment with osimertinib. This case indicates that afatinib is a potential trigger for BO. Clinical oncologists should therefore bear in mind the possible development of this potentially fatal adverse event in patients undergoing afatinib treatment; they should be alert to respiratory symptoms and consider periodic pulmonary function tests.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48036026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tracheal small cell carcinoma with RB1 Splice site mutation treated by chemoradiotherapy: A case report 放化疗治疗气管小细胞癌伴RB1剪接位点突变1例

Current problems in cancer. Case reports Pub Date : 2023-06-01 DOI: 10.1016/j.cpccr.2023.100245

Sho Sakamoto, Masahide Takeda, Yuka Izumiya, Yuji Okuda, Mariko Asano, Masaaki Sano, Kazuhiro Sato, Katsutoshi Nakayama

引用次数: 0

Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy 尽管卵巢功能抑制和双侧输卵管卵巢切除术，绝经前妇女接受abemaciclib后雌二醇水平的差异

Current problems in cancer. Case reports Pub Date : 2023-03-01 DOI: 10.1016/j.cpccr.2023.100224

Alaina J. Kessler , Rima Patel , Emily Jane Gallagher , Theresa Shao , Julie Fasano

{"title":"Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy","authors":"Alaina J. Kessler , Rima Patel , Emily Jane Gallagher , Theresa Shao , Julie Fasano","doi":"10.1016/j.cpccr.2023.100224","DOIUrl":"10.1016/j.cpccr.2023.100224","url":null,"abstract":"<div><p>Abemaciclib is approved for use in the adjuvant setting in combination with endocrine therapy for patients with high-risk, hormone receptor-positive, HER2-negative early-stage breast cancer based on the monarchE trial. Options for endocrine therapy for premenopausal women include an aromatase inhibitor with ovarian function suppression or tamoxifen with or without ovarian suppression. We describe a unique case of a premenopausal woman with early-stage breast cancer receiving adjuvant abemaciclib and an aromatase inhibitor with elevated estradiol levels as measured by the Abbott Alinity chemiluminescent immunoassay despite chemical and surgical ovarian function suppression. Given low estradiol levels using liquid chromatography-mass spectrometry testing following a bilateral salpingo-oopherectomy, our case report suggests an interference of abemaciclib with the Abbott Alinity immunoassay. This possible interference has significant impacts on clinical care as false elevations in estradiol levels measured by immunoassays can lead to unnecessary treatment changes, including surgery.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/6f/nihms-1883669.PMC10137258.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0